AnaptysBio (NASDAQ:ANAB) CEO Sells $662,267.34 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga sold 15,309 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $43.26, for a total transaction of $662,267.34. Following the completion of the sale, the chief executive officer directly owned 458,139 shares in the company, valued at approximately $19,819,093.14. This trade represents a 3.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Daniel Faga also recently made the following trade(s):

• On Wednesday, January 7th, Daniel Faga sold 9,202 shares of AnaptysBio stock. The shares were sold at an average price of $45.11, for a total value of $415,102.22.

AnaptysBio Price Performance

Shares of NASDAQ ANAB opened at $43.80 on Friday. AnaptysBio, Inc. has a 1 year low of $12.21 and a 1 year high of $52.47. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -15.53 and a beta of 0.32. The business has a 50-day moving average of $42.46 and a two-hundred day moving average of $31.30.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, topping the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The business had revenue of $76.32 million for the quarter, compared to analyst estimates of $15.83 million. As a group, equities research analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio declared that its board has initiated a share repurchase program on Friday, November 21st that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the biotechnology company to buy up to 9.6% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ANAB. Stifel Nicolaus decreased their target price on shares of AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, December 11th. HC Wainwright reduced their price target on AnaptysBio from $52.00 to $51.00 and set a “buy” rating for the company in a report on Monday, November 24th. Truist Financial boosted their price objective on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a report on Monday, November 10th. UBS Group assumed coverage on AnaptysBio in a report on Wednesday. They issued a “buy” rating and a $70.00 price target on the stock. Finally, Wells Fargo & Company lifted their price objective on AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, AnaptysBio has a consensus rating of “Moderate Buy” and an average price target of $60.40.

AnaptysBio News Roundup

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro (a GSK subsidiary)’s anticipatory breach claim in Delaware Chancery Court, which, if sustained, could reduce near‑term royalty exposure tied to Jemperli sales and lower legal risk. Reuters: AnaptysBio seeks partial dismissal GlobeNewswire: Motion to dismiss filing
• Positive Sentiment: Recent fundamentals and capital actions remain supportive: Anaptys reported an earnings and revenue beat in November and its board authorized up to $100M in share repurchases, which can support the share price over time by signaling management confidence and reducing outstanding float. MarketBeat ANAB coverage
• Neutral Sentiment: Upcoming event: CEO Daniel Faga will present at the J.P. Morgan Healthcare Conference (Jan. 13), which could catalyze new corporate updates or guidance but is unlikely to move the stock absent specific news. GlobeNewswire: JPM presentation
• Neutral Sentiment: Institutional positioning: Several funds have added or initiated positions recently, which can provide longer‑term demand but also increases the potential for large block trades to move the stock. MarketBeat ownership data
• Negative Sentiment: Insider selling: Multiple insiders (including the CEO and CFO) disclosed sizable sales on Jan. 5–7 that materially reduced their holdings; public Form 4 filings and media reports of these sales are likely contributing to today’s downward pressure as some investors view clustered insider sales negatively. InsiderTrades: insider selling alerts

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tudor Investment Corp ET AL grew its position in shares of AnaptysBio by 47.2% during the third quarter. Tudor Investment Corp ET AL now owns 13,869 shares of the biotechnology company’s stock worth $425,000 after acquiring an additional 4,450 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its stake in shares of AnaptysBio by 2.7% during the third quarter. Jacobs Levy Equity Management Inc. now owns 378,452 shares of the biotechnology company’s stock valued at $11,588,000 after acquiring an additional 10,005 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of AnaptysBio during the 3rd quarter valued at $315,000. Larson Financial Group LLC boosted its stake in AnaptysBio by 54.6% during the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 473 shares in the last quarter. Finally, Granahan Investment Management LLC lifted its holdings in AnaptysBio by 12.2% in the 3rd quarter. Granahan Investment Management LLC now owns 147,773 shares of the biotechnology company’s stock valued at $4,525,000 after acquiring an additional 16,118 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.